Correlation between clozapine use and metabolic syndrome in schizophrenic patients

Background: Clozapine, an atypical antipsychotic agent, is effective for relapse or refractory schizophrenia that has failed to respond other medications. Despite its effectiveness, clozapine a higher risk of metabolic syndrome than antipsychotics. Objective: This research aimed identify the correlation between and syndrome, such as obesity, cholesterol, blood glucose levels, in schizophrenic patients at Ghrasia Mental Hospital, Yogyakarta, Indonesia. Method: cross-sectional research. Subjects who met inclusion criteria were randomly sampled from outpatients November 2021 February 2022. The collected medical record data (characteristic patients, medication patterns, body mass index) analysed profiles (cholesterol levels). descriptively statistically. Result: Among 71 this research, 37 (52.11%) male 34 (47.89%) female, with average age 36-45 years. treatment patterns follows: 44 taking only 27 did not use clozapine. Clozapine was frequently combined risperidone haloperidol Bivariate analysis using Fisher's Exact test revealed no significant use, regimen (single combined), duration therapy (>= 5 years), dose (high low) hypercholesterolemia, hyperglycemia. Meanwhile, multivariate gender obesity (p < 0.05), women having 0.299 men. effects on hypercholesterolemia hyperglycemia insignificant. Conclusion: There found syndrome. Gender have